SCHEMBL724650

SCHEMBL724650

COC(=O)c1sc(N2CCOC(C)C2)nc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 5/20 0.39
GAA P10253 2/20 0.39
PIK3CD O00329 2/20 0.37
PIK3CB P42338 2/20 0.37
PIK3CA P42336 1/20 0.37
POLB P06746 2/20 0.36
HPGD P15428 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PIK3CG P48736 1/20 0.34
FFAR2 O15552 1/20 0.34
GAK O14976 3/20 0.33
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
AKT1 P31749 1/20 0.33
PABPC1 P11940 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725151 0.82 MAPT (0.66) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL2547518 0.75 HRH3 (0.47) L3MBTL1
SCHEMBL24829780 0.75 ALDH1A1 (0.54) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL31302551 0.68 SMN1; SMN2 (0.38) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL11005931 0.68 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1KDM4EGAAPIK3CA
SCHEMBL2878426 0.67 ALDH1A1 (0.52) MAPTSMN1; SMN2ALDH1A1KDM4EPIK3CA
SCHEMBL2551286 0.67 ALDH1A1 (0.42) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL31320207 0.67 KIF18A (0.45) KDM4EPIK3CDPIK3CBPIK3CAPIK3CG
SCHEMBL27191747 0.67 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL31302530 0.66 ALDH1A1 (0.39) MAPTSMN1; SMN2ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432321-B1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-06-14 EP disclosed
EP-2432321-B1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-06-14 EP disclosed
US-8410095-B2 Thiazolopyrimidinone derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-04-02 US disclosed
US-8410095-B2 Thiazolopyrimidinone derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-04-02 US disclosed
US-8410095-B2 Thiazolopyrimidinone derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-04-02 US disclosed
EP-2432321-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GlaxoSmithKline LLC (US) 2012-03-28 EP disclosed
US-20120053147-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-03-01 US disclosed
US-20120053147-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-03-01 US disclosed
US-20120053147-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-03-01 US disclosed
WO-2010135504-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-11-25 WO disclosed
WO-2010135504-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053147-A1 THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CA, PI4KA MAPT 3699/4885SMN1; SMN2 4638/4885ALDH1A1 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.